Literature DB >> 3774726

Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.

C J Gibbs, M Peacock.   

Abstract

We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD [(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate]. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly normalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774726      PMCID: PMC2419051          DOI: 10.1136/pgmj.62.732.937

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Hypercalcaemia. Management.

Authors:  P C Selby; M Peacock; D H Marshall
Journal:  Br J Hosp Med       Date:  1984-03

2.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis.

Authors:  J S Adams; O P Sharma; M A Gacad; F R Singer
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

3.  Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.

Authors:  P H Reitsma; O L Bijvoet; H Verlinden-Ooms; L J van der Wee-Pals
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

  3 in total
  8 in total

1.  Tumoral calcinosis associated with hypercalcemia in a patient with chronic renal failure.

Authors:  Ryoko Horikoshi; Tetsu Akimoto; Daishi Meguro; Osamu Saito; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-10-23       Impact factor: 2.801

2.  Exploring the relationship between vitamin D and basic personality traits.

Authors:  Andrea Ubbenhorst; Sarah Striebich; Florian Lang; Undine E Lang
Journal:  Psychopharmacology (Berl)       Date:  2011-01-29       Impact factor: 4.530

3.  Long-term management of hypercalcaemia in chronically active sarcoidosis.

Authors:  R N Sinha; W D Fraser; I F Casson
Journal:  J R Soc Med       Date:  1997-03       Impact factor: 5.344

Review 4.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.

Authors:  N Varache; M Audran; P Clochon; A Lortholary; G Bouachour; P Alquier; M F Basle
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

Review 7.  Metabolic Disorders in Chronic Lung Diseases.

Authors:  Ourania Papaioannou; Theodoros Karampitsakos; Ilianna Barbayianni; Serafeim Chrysikos; Nikos Xylourgidis; Vasilis Tzilas; Demosthenes Bouros; Vasilis Aidinis; Argyrios Tzouvelekis
Journal:  Front Med (Lausanne)       Date:  2018-01-18

8.  BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA.

Authors:  Roselyn Cristelle Isidro Mateo; Ricardo Ortiz; Harold Noah Rosen
Journal:  AACE Clin Case Rep       Date:  2019-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.